Study: NCT01366534

Adverse event: Fatigue (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 28 at risk

Adverse event: Malaise (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 28 at risk

Adverse event: Pain (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 5 affected / 28 at risk

Adverse event: Nasopharyngitis (post-vaccination)
Serious: no
Organ System: Infections and infestations
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 28 at risk

Adverse event: Upper respiratory tract infection (post-vaccination)
Serious: no
Organ System: Infections and infestations
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 6 affected / 28 at risk

Adverse event: Arthralgia (post-vaccination)
Serious: no
Organ System: Musculoskeletal and connective tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 1 affected / 28 at risk

Adverse event: Back pain (post-vaccination)
Serious: no
Organ System: Musculoskeletal and connective tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 4 affected / 28 at risk

Adverse event: Headache (post-vaccination)
Serious: no
Organ System: Nervous system disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 3 affected / 28 at risk

Adverse event: Dysmenorrhoea (post-vaccination)
Serious: no
Organ System: Reproductive system and breast disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 3 affected / 28 at risk

Adverse event: Nasal congestion (post-vaccination)
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 1 affected / 28 at risk

Adverse event: Throat irritation
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 28 at risk

Adverse event: Pruritus (post-vaccination)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 28 at risk

Adverse event: Malaria (post-challenge)
Serious: no
Organ System: Infections and infestations
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 14 affected / 25 at risk

Adverse event: Headache (post-challenge)
Serious: no
Organ System: Nervous system disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 5 affected / 25 at risk

Adverse event: Oropharyngeal pain(post-challenge)
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 3 affected / 25 at risk

Adverse event: Nausea (post-challenge)
Serious: no
Organ System: Gastrointestinal disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 1 affected / 25 at risk

Adverse event: Upper respiratory tract infection (post-challenge)
Serious: no
Organ System: Infections and infestations
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 1 affected / 25 at risk

Adverse event: Pruritus (post-challenge)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 1 affected / 25 at risk

Adverse event: Pain- solicited local (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 27 affected / 28 at risk

Adverse event: Redness (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 15 affected / 28 at risk

Adverse event: Swelling (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 13 affected / 28 at risk

Adverse event: Chills (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 15 affected / 28 at risk

Adverse event: Fatigue (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 15 affected / 28 at risk

Adverse event: Gastrointestinal symptoms (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 5 affected / 28 at risk

Adverse event: Headache- solicited general (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 21 affected / 28 at risk

Adverse event: Temperature (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 6 affected / 28 at risk

Adverse event: Nausea (post-vaccination)
Serious: no
Organ System: Gastrointestinal disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 27 at risk

Adverse event: Malaise (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 1 affected / 27 at risk

Adverse event: Pain (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 27 at risk

Adverse event: Nasopharyngitis (post-vaccination)
Serious: no
Organ System: Infections and infestations
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 5 affected / 27 at risk

Adverse event: Upper respiratory tract infection (post-vaccination)
Serious: no
Organ System: Infections and infestations
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 5 affected / 27 at risk

Adverse event: Arthralgia (post-vaccination)
Serious: no
Organ System: Musculoskeletal and connective tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 27 at risk

Adverse event: Back pain (post-vaccination)
Serious: no
Organ System: Musculoskeletal and connective tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 1 affected / 27 at risk

Adverse event: Headache (post-vaccination)
Serious: no
Organ System: Nervous system disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 4 affected / 27 at risk

Adverse event: Dysmenorrhoea (post-vaccination)
Serious: no
Organ System: Reproductive system and breast disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 1 affected / 27 at risk

Adverse event: Nasal congestion (post-vaccination)
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 4 affected / 27 at risk

Adverse event: Hyperhidrosis (post-vaccination)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 3 affected / 27 at risk

Adverse event: Pruritus (post-vaccination)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 2 affected / 27 at risk

Adverse event: Malaria (post-challenge)
Serious: no
Organ System: Infections and infestations
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 10 affected / 21 at risk

Adverse event: Headache (post-challenge)
Serious: no
Organ System: Nervous system disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 7 affected / 21 at risk

Adverse event: Nausea (post-challenge)
Serious: no
Organ System: Gastrointestinal disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 2 affected / 21 at risk

Adverse event: Upper respiratory tract infection (post-challenge)
Serious: no
Organ System: Infections and infestations
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 2 affected / 21 at risk

Adverse event: Pruritus (post-challenge)
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 2 affected / 21 at risk

Adverse event: Pain- solicited local (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 26 affected / 27 at risk

Adverse event: Redness (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 11 affected / 27 at risk

Adverse event: Swelling (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 11 affected / 27 at risk

Adverse event: Chills (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 13 affected / 27 at risk

Adverse event: Fatigue (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 17 affected / 27 at risk

Adverse event: Gastrointestinal symptoms (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 6 affected / 27 at risk

Adverse event: Headache- solicited general (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 14 affected / 27 at risk

Adverse event: Temperature (post-vaccination)
Serious: no
Organ System: General disorders
Notes: Subjects from Control Group did not receive any vaccination.
Frequency: 9 affected / 27 at risk

Adverse event: Malaria (post-challenge)
Serious: no
Organ System: Infections and infestations
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 12 affected / 12 at risk

Adverse event: Headache (post-challenge)
Serious: no
Organ System: Nervous system disorders
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 2 affected / 12 at risk

Adverse event: Upper respiratory tract infection (post-challenge)
Serious: no
Organ System: Infections and infestations
Notes: For the post-challenge period, 25 subjects from AD35.CS.01 Group and 21 subjects from GSK257049 Group participated in the challenge procedures and had results available.
Frequency: 2 affected / 12 at risk